peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GLP-2 analog

Apraglutide

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

Apraglutide is an analog of glucagon-like peptide-2 (GLP-2) under clinical development for treating short bowel syndrome with intestinal failure (SBS-IF). A Phase 1 open-label, nonrandomized, single-dose design evaluated apraglutide 3.5 mg in moderate hepatic impairment (Child-Pugh B) versus normal hepatic function.

Sources for this introduction: [1] [2]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Apraglutide is an analog of glucagon-like peptide-2 (GLP-2) under clinical development for treating short bowel syndrome with intestinal failure (SBS-IF).

Sources[1]pubmedPharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial.Apraglutide is a glucagon-like peptide-2 (GLP-2) analog in clinical development for the treatment of patients with SBS-IF.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Apraglutide is a glucagon-like peptide-2 (GLP-2) analog in clinical development for the treatment of patients with SBS-IF.”

    Pharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial. · Abstract

    pubmed:41545784:ca0e2ecdc63f:ca0e2ecdc63f

How does it work?

Target, response, and disposition.

Pharmacokinetics

A Phase 1 open-label, nonrandomized, single-dose design evaluated apraglutide 3.5 mg in moderate hepatic impairment (Child-Pugh B) versus normal hepatic function.

Sources[1]pubmedPharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial.In this Phase 1, open-label, nonrandomized, single-dose trial, apraglutide 3.5 mg was administered to participants with moderate hepatic impairment (Child-Pugh B) or normal hepatic function.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “In this Phase 1, open-label, nonrandomized, single-dose trial, apraglutide 3.5 mg was administered to participants with moderate hepatic impairment (Child-Pugh B) or normal hepatic function.”

    Pharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial. · Abstract

    pubmed:41545784:ca0e2ecdc63f:ca0e2ecdc63f

Pharmacokinetics

Overall apraglutide exposure (AUCinf) was lower with moderate hepatic impairment (4086 vs 5351 h·ng/mL).

Sources[1]pubmedPharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial.AUCinf= 4086 vs 5351 h ng/mL, respectively).
Reported result
AUCinf= 4086 vs 5351 h ng/mL
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “AUCinf= 4086 vs 5351 h ng/mL, respectively).”

    Pharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial. · Abstract

    pubmed:41545784:ca0e2ecdc63f:ca0e2ecdc63f

Pharmacokinetics

Moderate hepatic impairment was associated with reduced peak plasma concentration (Cmax) of apraglutide compared with normal hepatic function (58.7 vs 71.3 ng/mL).

Sources[1]pubmedPharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial.A lower Cmaxand AUCinfof apraglutide was observed in individuals with moderate hepatic impairment versus those with normal hepatic function (Cmax= 58.7 vs 71.3 ng/mL; AUCinf= 4086 vs 5351 h ng/mL, respectively).
Reported result
Cmax= 58.7 vs 71.3 ng/mL
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “A lower Cmaxand AUCinfof apraglutide was observed in individuals with moderate hepatic impairment versus those with normal hepatic function (Cmax= 58.7 vs 71.3 ng/mL; AUCinf= 4086 vs 5351 h ng/mL, respectively).”

    Pharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial. · Abstract

    pubmed:41545784:ca0e2ecdc63f:ca0e2ecdc63f

Pharmacokinetics

Moderate hepatic impairment was associated with reduced total exposure (AUCinf) to apraglutide compared with normal hepatic function (4086 vs 5351 h ng/mL).

Sources[1]pubmedPharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial.A lower Cmaxand AUCinfof apraglutide was observed in individuals with moderate hepatic impairment versus those with normal hepatic function (Cmax= 58.7 vs 71.3 ng/mL; AUCinf= 4086 vs 5351 h ng/mL, respectively).
Reported result
AUCinf= 4086 vs 5351 h ng/mL
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “A lower Cmaxand AUCinfof apraglutide was observed in individuals with moderate hepatic impairment versus those with normal hepatic function (Cmax= 58.7 vs 71.3 ng/mL; AUCinf= 4086 vs 5351 h ng/mL, respectively).”

    Pharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial. · Abstract

    pubmed:41545784:ca0e2ecdc63f:ca0e2ecdc63f

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, mechanism, regulatory, safety
  • 110 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (56), assurance_score_below_0.72 (50), current_regulatory_source_required (21), extraction_ambiguity (45), high_risk_requires_regulatory_or_two_independent_sources (51), no_direct_support (104), proposal_not_staged (4)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Pharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial. ↗

    pubmed · published 2026-01-01 · retrieved 2026-08-25T22:43:25Z

Publication history and provenance

Version 5 · Automated assessment · 2026-08-25T22:43:25Z

a66d8e071cb64488bfae1877e9e3904a77b95b38512c0e587fe47044a945680f